lymphoma

[npj Precision Oncology] STAT3 inhibition effectively suppressed the adaptive survival of anaplastic lymphoma kinase (ALK)-rearranged lung cancer cells by enhancing ALK inhibition-induced apoptosis.

[Therapeutic Advances in Hematology] Investigators provided an overview for the available management strategies for relapsed mantle cell lymphoma (MCL) and examines the role of CAR T cell in the current and future treatment of MCL.

[Biochemical Pharmacology] Investigators summarize recent progress in relevant studies regarding the physiological and pathophysiological functions of MALT1, post-translational modifications of MALT1 and its role in B cell- and T cell- related diseases.

[Science Signaling] Researchers demonstrated that PKCθ/β-dependent CARD11 phosphorylation also suppressed CARD11 functions in T or B cells.

[BeiGene] BeiGene announced that the US FDA has accepted a supplemental new drug application or BRUKINSA® for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

[Molecular Biology Reports] Researchers assessed the suppressing effect of VGB4, a vascular endothelial growth factor (VEGF) antagonist peptide with the binding ability to both VEGF receptor1 and VEGF receptor2, on VEGF-induced proliferation and migration of the human lung adenocarcinoma cell line A549 and the human colon adenocarcinoma cell line HT29.